Literature DB >> 29761239

Kinetics and Characterization of Non-enzymatic Fragmentation of Monoclonal Antibody Therapeutics.

Sahithi Ravuluri1, Rohit Bansal1, Nidhi Chhabra1, Anurag S Rathore2.   

Abstract

PURPOSE: To understand non-enzymatic hydrolytic fragmentation of a monoclonal antibody therapeutic under temperature stressed conditions and investigating possible mechanism for the same.
METHODS: The mAb therapeutic was incubated at 50°C in phosphate buffer at pH 6.5 and fragmentation was monitored at different ionic strengths under stressed conditions. The incubated mAb was sampled at regular time intervals by analytical Size Exclusion Chromatography (SEC).
RESULTS: It was observed that 57% of the mAb product fragmented over 4 days into two fragment species - Fc-Fab and Fab with molecular weights of 97 KDa and 47 KDa, respectively, as measured by mass spectrometry (MS) and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The fragmentation rate was slow initially and then accelerated with time. No change in % aggregate level was observed in this duration, implying that degradation was primarily via fragmentation at high temperature. Kinetics of hydrolytic fragmentation was hypothesized and SEC data was fitted to estimate the kinetic rate constants. While degradation of the monomer into fragment species was non-Arrhenius with a negative activation energy, further degradation of Fab-Fc fragments into Fab or Fc fragments followed Arrhenius Law with an activation energy of 2.1 and 15.38 kcal/mol, respectively.
CONCLUSION: High temperature (50°C) causes mAb to cleave at the hinge region to form Fab-Fc and Fab/Fc, as confirmed by dynamic light scattering, SDS-PAGE, SEC, and MS. A kinetic model for hydrolytic fragmentation has been proposed. The results are expected to assist end users in formulation development as well as in monitoring stability of biotherapeutic products.

Entities:  

Keywords:  fragmentation; kinetic modeling; mass spectrometry; monoclonal antibodies; size exclusion chromatography

Mesh:

Substances:

Year:  2018        PMID: 29761239     DOI: 10.1007/s11095-018-2415-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Investigating the Degradation Behaviors of a Therapeutic Monoclonal Antibody Associated with pH and Buffer Species.

Authors:  Songyan Zheng; Difei Qiu; Monica Adams; Jinjiang Li; Rao V Mantri; Rajesh Gandhi
Journal:  AAPS PharmSciTech       Date:  2015-09-04       Impact factor: 3.246

Review 2.  Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies.

Authors:  Ulf Nobbmann; Malcolm Connah; Brendan Fish; Paul Varley; Chris Gee; Sandrine Mulot; Juntao Chen; Liang Zhou; Yanling Lu; Fei Shen; Junming Yi; Stephen E Harding
Journal:  Biotechnol Genet Eng Rev       Date:  2007

Review 3.  The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals.

Authors:  Tsutomu Arakawa; Daisuke Ejima; Tiansheng Li; John S Philo
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

4.  Aggregation stability of a monoclonal antibody during downstream processing.

Authors:  Paolo Arosio; Giuliano Barolo; Thomas Müller-Späth; Hua Wu; Massimo Morbidelli
Journal:  Pharm Res       Date:  2011-03-30       Impact factor: 4.200

5.  Avoiding antibody aggregation during processing: establishing hold times.

Authors:  Varsha Joshi; Tarun Shivach; Vijesh Kumar; Nitin Yadav; Anurag Rathore
Journal:  Biotechnol J       Date:  2014-05-12       Impact factor: 4.677

6.  Metal ion interactions with mAbs: Part 1.

Authors:  Zephania Kwong Glover; Louisette Basa; Benjamin Moore; Jennifer S Laurence; Alavattam Sreedhara
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 7.  Non-Arrhenius protein aggregation.

Authors:  Wei Wang; Christopher J Roberts
Journal:  AAPS J       Date:  2013-04-25       Impact factor: 4.009

8.  Investigation of monoclonal antibody fragmentation artifacts in non-reducing SDS-PAGE.

Authors:  Zhiqing C Zhu; Yingchen Chen; Michael S Ackerman; Bei Wang; Wei Wu; Bo Li; Linda Obenauer-Kutner; Rulin Zhao; Li Tao; Peter M Ihnat; Jinping Liu; Rajesh B Gandhi; Bo Qiu
Journal:  J Pharm Biomed Anal       Date:  2013-04-28       Impact factor: 3.935

9.  Fragmentation of a recombinant monoclonal antibody at various pH.

Authors:  Georgeen Gaza-Bulseco; Hongcheng Liu
Journal:  Pharm Res       Date:  2008-05-13       Impact factor: 4.200

10.  Quality control and stability studies with the monoclonal antibody, trastuzumab: application of 1D- vs. 2D-gel electrophoresis.

Authors:  Dashnor Nebija; Christian R Noe; Ernst Urban; Bodo Lachmann
Journal:  Int J Mol Sci       Date:  2014-04-15       Impact factor: 5.923

View more
  2 in total

1.  Uncommon Peptide Bond Cleavage of Glucagon from a Specific Vendor under near Neutral to Basic Conditions.

Authors:  Hong-Jian Zheng; Bin-Bin Shen; Jing Wang; Haibin Wang; Guo-Li Huo; Li-Rui Huang; Jian-Qing Gao; Wei-Jie Fang
Journal:  Pharm Res       Date:  2019-06-03       Impact factor: 4.200

2.  Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.

Authors:  Ryuta Wada; Makoto Matsui; Nana Kawasaki
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.